Prolactin and alteration of fertility

Česká verze

Authors: M. Štelcl ¹; P. Vrublovský ²; Š. Machač ²
Authors place of work: Reprogenesis, Brno, vedoucí lékař MUDr. M. Štelcl ¹; IVF Clinic, Olomouc, vedoucí lékař MUDr. Š. Machač, Ph. D. ²
Published in the journal: Ceska Gynekol 2018; 83(3): 232-235

Summary

Aim:

Physiology and pathology of prolactin production, clinical consequences.

Design:

Review.

Setting:

Reprogenesis International, Brno.

Methods:

Study of current literature.

Conclusion:

In article is discussed physiology and pathology of prolactin production, influence of hyperprolactinaemia to ovarian function –⁠ anovulation, irregularities of cycle, amenorrhea. Separately is discussed problem of microprolactinoma and prolactinoma. Review of current therapeutic possibilities.

Keywords:

prolactin, hyperprolactinaemia, microprolactinoma, prolactinoma

Zdroje

1. Casanueva, FF., Mark, E., Molitch, ME., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol, 2006, 65, p. 265–273.

2. Čedíkova, M., Babuška, V., Rajdl, D., et al. Srovnaní hladin prolaktinu, fT3 a fT4 ve folikulární tekutině žen s poruchou plodnosti a zdravých plodných dárkyň oocytů. Čes Gynek, 2012, 5, s. 471–476.

3. Freeman, ME., et al. Prolactin: structure, function, and regulation of secretion, Physiol Rev, 2000 80, 4, p. 1523–631.

4. Ganong, WF., et al. Přehled lékařské fyziologie. Praha, Galén, 1995, s. 356–358

5. Ježková, J., Hána, V., Kršek, M., Weiss, V., et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Ednocrinol, 2009, 70, 5, p. 732–741.

6. Jones, J., Bashir, T., Olney, J., et al. Cabergoline treatment for a large macroprolactinoma throughout pregnancy. J Obstet Gynecol, 1997, 17, p. 375–376.

7. Klibanski, A., Biller, B., Rosenthal, M., et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab, 1988, 67, p. 124–130.

8. Marek, J. Základy gynekologické endokrinologie. Praha, Grada, 2002, s. 137–150.

9. Molitch, ME. Medication-induced hyperprolactinaemia. Mayo Clinic Proceedings, 2005, 80, p. 1050–1057.

10. Molitch, ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2002, 5, p. 55–65.

11. Schlechte, JA. Clinical practice. Prolactinoma. New Engl J Med, 2003, 349, p. 2035–2041.

12. Stalldecker, G., et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary, 2010, 13, 4, p. 345–350.

13. Verhelst, J., Abs, R. Hyperprolactinaemia: pathophysiology and management. Treat Endocrinol, 2003, 2, p. 23–32.

14. Webster, J., Pisciteli, G., Polli, A., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl J Med, 1994, 6, p. 904–909